Literature DB >> 28490259

Recent amendments to NICE's value-based assessment of health technologies: implicitly inequitable?

Mike Paulden1.   

Abstract

Keywords:  NICE; equity; health technology assessment; opportunity cost; value

Mesh：

Year:  2017        PMID： 28490259     DOI： 10.1080/14737167.2017.1330152

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN： 1473-7167            Impact factor:   2.217


× No keyword cloud information.
  16 in total

1.  How should clinicians interpret conflicting cost-effectiveness analyses for the treatment of lymphoma across nations and payer models?

Authors:  R Andrew Harkins; Christopher R Flowers
Journal:  Leuk Lymphoma       Date:  2020-11-04

2.  Incorporating Equity Concerns in Cost-Effectiveness Analyses: A Systematic Literature Review.

Authors:  Thomas Ward; Ruben E Mujica-Mota; Anne E Spencer; Antonieta Medina-Lara
Journal:  Pharmacoeconomics       Date:  2021-10-29       Impact factor: 4.981

3.  Affordability and Value in Decision Rules for Cost-Effectiveness: A Survey of Health Economists.

Authors:  Alyssa Bilinski; Evan MacKay; Joshua A Salomon; Ankur Pandya
Journal:  Value Health       Date:  2022-02-24       Impact factor: 5.101

Review 4.  The future of cystic fibrosis care: a global perspective.

Authors:  Scott C Bell; Marcus A Mall; Hector Gutierrez; Milan Macek; Susan Madge; Jane C Davies; Pierre-Régis Burgel; Elizabeth Tullis; Claudio Castaños; Carlo Castellani; Catherine A Byrnes; Fiona Cathcart; Sanjay H Chotirmall; Rebecca Cosgriff; Irmgard Eichler; Isabelle Fajac; Christopher H Goss; Pavel Drevinek; Philip M Farrell; Anna M Gravelle; Trudy Havermans; Nicole Mayer-Hamblett; Nataliya Kashirskaya; Eitan Kerem; Joseph L Mathew; Edward F McKone; Lutz Naehrlich; Samya Z Nasr; Gabriela R Oates; Ciaran O'Neill; Ulrike Pypops; Karen S Raraigh; Steven M Rowe; Kevin W Southern; Sheila Sivam; Anne L Stephenson; Marco Zampoli; Felix Ratjen
Journal:  Lancet Respir Med       Date:  2019-09-27       Impact factor: 30.700

Review 5.  A systematic review of moral reasons on orphan drug reimbursement.

Authors:  Bettina M Zimmermann; Johanna Eichinger; Matthias R Baumgartner
Journal:  Orphanet J Rare Dis       Date:  2021-06-30       Impact factor: 4.123

6.  Comparable worth of life for all? Conducting and disseminating health economic evaluations for refugees in Germany.

Authors:  Louise Biddle; Katharina Wahedi; Kayvan Bozorgmehr
Journal:  Global Health       Date:  2022-05-12       Impact factor: 10.401

7.  A flexible formula for incorporating distributive concerns into cost-effectiveness analyses: Priority weights.

Authors:  Øystein Ariansen Haaland; Frode Lindemark; Kjell Arne Johansson
Journal:  PLoS One       Date:  2019-10-10       Impact factor: 3.240

8.  A non-stationary Markov model for economic evaluation of grass pollen allergoid immunotherapy.

Authors:  Massimo Bilancia; Giuseppe Pasculli; Danilo Di Bona
Journal:  PLoS One       Date:  2020-05-14       Impact factor: 3.240

9.  Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to the 10-Valent Pneumococcal Conjugate Vaccine (PCV10) in Italy.

Authors:  Filippo Ansaldi; Sarah Pugh; Daniela Amicizia; Roberto Di Virgilio; Cecilia Trucchi; Andrea Orsi; Alessandro Zollo; Giancarlo Icardi
Journal:  Pathogens       Date:  2020-01-22

10.  Evaluation of the cost-effectiveness of dexrazoxane for the prevention of anthracycline-related cardiotoxicity in children with sarcoma and haematologic malignancies: a European perspective.

Authors:  Sarah Dewilde; Kevin Carroll; Emilia Nivelle; James Sawyer
Journal:  Cost Eff Resour Alloc       Date:  2020-02-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.